FRA
BNTX icon

Front Row Advisors’s BioNTech BNTX Stock Holding History

Front Row Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.42K Hold
80
– – ﹤0.01% 429
2026
Q1 		$7.11K Hold
80
– – ﹤0.01% 427
2025
Q4 		$7.62K Hold
80
– – ﹤0.01% 410
2025
Q3 		$7.89K Hold
80
– – ﹤0.01% 408
2025
Q2 		$8.52K Buy
+80
New +$8.08K ﹤0.01% 390

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

Front Row Advisors's BNTX Position: Q2 2026 in Review

Front Row Advisors held its BioNTech (BNTX) position steady in Q2 2026 at 80 shares worth $7.42K. The position accounts for ﹤0.01% of the portfolio, ranked #429.

Front Row Advisors first reported a position in BNTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $8.52K in Q2 2025. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Front Row Advisors held 80 shares of BioNTech worth $7.42K as of Q2 2026.
  • Front Row Advisors left its BioNTech share count unchanged in Q2 2026.
  • BioNTech made up ﹤0.01% of Front Row Advisors's portfolio in Q2 2026, its #429 holding.
  • Front Row Advisors first reported a position in BioNTech in Q2 2025 and has held it in 5 quarters since.
  • Front Row Advisors's BioNTech position peaked at $8.52K in Q2 2025.
  • 283 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.